Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07537049) titled 'BR101 in Patients With Relapsed/Refractory Multiple Myeloma' on April 12.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Condition: Multiple Myeloma (MM)

Intervention: Biological: BR101 injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 30, 2026

Target Sample Size: 10

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07537049

Pub...